Resistance to Targeted Therapies in Breast Cancer

This book will provide an in-depth description of resistance to targeted therapies in breast cancerThis book will discuss targeted therapies used to treat ER+ or Her2+ breast cancers (i.e. Tamoxifen or trastuzumab)This book will also discuss targeting signaling pathways activated in triple negative breast cancer (i.e. EGFR and Wnt signaling)This book will give insight into the landscape of breast cancer treatment and the challenges of targeted therapyThis book will provide a glimpse into the future of breast cancer therapy

Verwandte Artikel